Simulations Plus (SLP) Projected to Post Earnings on Monday

Simulations Plus (NASDAQ:SLP) is expected to issue its Q3 2025 quarterly earnings data after the market closes on Monday, July 14th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $22.83 million for the quarter.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.06. The company had revenue of $22.43 million for the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a net margin of 9.18% and a return on equity of 7.86%. Simulations Plus’s revenue was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.20 EPS. On average, analysts expect Simulations Plus to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Simulations Plus Trading Down 2.5%

NASDAQ:SLP opened at $17.91 on Monday. Simulations Plus has a twelve month low of $16.72 and a twelve month high of $44.33. The company’s 50 day moving average is $26.47 and its two-hundred day moving average is $28.76. The company has a market cap of $360.07 million, a PE ratio of 51.16 and a beta of 0.83.

Analysts Set New Price Targets

Several analysts have commented on SLP shares. William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Tuesday, June 3rd. KeyCorp lifted their price objective on shares of Simulations Plus from $32.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, April 16th. JMP Securities reiterated a “market perform” rating on shares of Simulations Plus in a research note on Wednesday, June 18th. Wall Street Zen upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a research note on Monday, April 28th. Finally, Craig Hallum decreased their target price on shares of Simulations Plus from $45.00 to $36.00 and set a “buy” rating for the company in a research note on Friday, June 13th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Simulations Plus currently has a consensus rating of “Moderate Buy” and an average target price of $41.25.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the sale, the director owned 3,344,157 shares of the company’s stock, valued at approximately $112,062,701.07. The trade was a 0.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 19.40% of the company’s stock.

Institutional Investors Weigh In On Simulations Plus

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLP. Royal Bank of Canada increased its holdings in Simulations Plus by 26.6% in the 1st quarter. Royal Bank of Canada now owns 114,885 shares of the technology company’s stock worth $2,817,000 after acquiring an additional 24,132 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Simulations Plus by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after acquiring an additional 390 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Simulations Plus in the 1st quarter worth $255,000. Finally, Woodline Partners LP increased its holdings in Simulations Plus by 32.1% in the 1st quarter. Woodline Partners LP now owns 13,239 shares of the technology company’s stock worth $325,000 after acquiring an additional 3,220 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.